Authors demonstrated that rigosertib induced toxicity in HNSCC cell lines, inhibiting PI3K/Akt/mTOR pathways in a dose-dependent manner, which ultimately led to the inhibition of cell-cycle progression. Here, AKT1 is linked to head and neck squamous cell carcinoma.